Brookline Capital Markets Stock Recommendations and Price Targets

This is a list of recent ratings by Brookline Capital Markets.

Date	Company Name	Action	Current Price	Price Target	Rating
10/29/2026	KYMR Kymera Therapeutics	Reiterated Rating	$127.00		Buy ➝ Buy
10/7/2026	BMEA Biomea Fusion	Initiated Coverage	$1.00		Buy
10/7/2026	CRBU Caribou Biosciences	Downgrade	$0.00		Buy ➝ Hold
9/28/2026	RVMD Revolution Medicines	Initiated Coverage	$194.00	$318.00	Buy
8/19/2026	MRNA Moderna	Reiterated Rating	$228.00		Buy ➝ Buy
7/31/2026	SCYX SCYNEXIS	Reiterated Rating	$4.00		Buy ➝ Buy
7/28/2026	LNTH Lantheus	Downgrade	$101.00		Strong-Buy ➝ Hold
7/12/2026	CLRB Cellectar Biosciences	Upgrade	$1.00		Strong-Buy
6/29/2026	EDSA Edesa Biotech	Upgrade	$2.00		Strong-Buy
6/11/2026	ADIL Adial Pharmaceuticals	Downgrade	$5.00		Strong-Buy ➝ Hold
6/8/2026	KYMR Kymera Therapeutics	Reiterated Rating	$127.00		Buy ➝ Buy
5/20/2026	PMN Promis Neurosciences	Upgrade	$3.00		Strong-Buy
5/7/2026	ERNA Ernexa Therapeutics	Initiated Coverage	$2.00	$30.00	Buy